Protalix BioTherapeutics Reports Second Quarter 2023 Financi

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

Related Keywords

Israel , United States , Carmiel , Ha Afon , Fiocruz , Estado Do Rio , Brazil , New Zealand , American , Giacomo Chiesi , Chuck Padala , Chiesi Farmaceutici , Dror Bashan , Ankit Mehta , Pfizer , Pfizer Inc , Protalix Biotherapeutics Inc , Chiesi Group , European Medicines Agency , Israel Innovation Authority , Zealand Clinical Research , Protalix Biotherapeutics , Company First In Human , European Union , Company Link , Disability Ethics Committee , Devices Safety Authority Medsafe , Drug Administration , Prnewswire Protalix Biotherapeutics Inc , Exchange Commission , Baylor University Medical Center , European Commission , Chief Executive , Chiesi Global Rare Diseases , Recent Business , New Zealand Clinical Research , New Zealand Medicines , Medical Devices Safety Authority , Chiesi Global Rare , Biologics License Application , Marketing Authorization Application , Tax Cuts , Jobs Act , Call Details , Events Calendar , Private Securities Litigation Reform Act , Nc ,